Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
2017 Seen as a Challenge for Teva (TEVA), But Sticking with 'Buy' - Maxim
November 16, 2016 8:25 AM ESTMaxim Group analyst Gabrielle Zhou lowered her price target on Teva Pharma (NYSE: TEVA) to $52.00 (from $72.00) but maintained a Buy rating following results. The firm sees 2017 as a challenge.
Zhou commented:
Teva reported 3Q16 with total revenues of $5.6B, with $2.9B in generic product revenues, including $887M from the Actavis generic business (transaction completed on Aug. 2, 2016). Total generic revenues increased 26% sequentially, compared to $2.3B in 2Q16. Specialty revenues were $2B, down 10%... MoreJefferies Downgrades Teva Pharma (TEVA) to Hold; Too Many Headwinds
November 16, 2016 6:32 AM ESTJefferies downgraded Teva Pharma (NYSE: TEVA) from Buy to Hold with a price target of $40.00 (from $69.00), saying there are too many headwinds.
Analyst David Steinberg commented, "Our view has changed. We now think there is little over the next year... More
Teva Pharma (TEVA): Concerns on Generics Overdone - Guggenheim
November 15, 2016 10:26 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $80 price target on Teva Pharma (NYSE: TEVA) following results. The analyst said concerns that generic sales are disappearing are overdone.
Chen commented, "TEVA reported a 3Q16 beat, underscoring our belief that its execution is still... More
